

Tragedy, Perseverance, and Chance “The Story of CA

New England Journal of Medicine

377, 1313-1315

DOI: 10.1056/nejmp1711886

Citation Report

#	ARTICLE	IF	CITATIONS
1	Clinical trials of CAR-T cells in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 166.	6.9	62
2	Immunotherapy Frontiers in Hematology. <i>HemaSphere</i> , 2017, 1, e8.	1.2	2
3	Promises and challenges of immuno-oncology from a clinical perspective. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 101-102.	0.6	1
4	La decisi3n cl3nica: clave de los resultados de los servicios de salud en cualquier pa3s. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 515-519.	0.6	2
5	Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy. <i>Medicine (United States)</i> , 2018, 97, e0455.	0.4	8
6	Beginning the CAR T cell therapy revolution in the US and EU. <i>Current Research in Translational Medicine</i> , 2018, 66, 62-64.	1.2	24
7	The revving up of CARs. <i>Gene Therapy</i> , 2018, 25, 162-162.	2.3	6
8	Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation. <i>Cytotherapy</i> , 2018, 20, 453-460.	0.3	14
9	Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. <i>Molecular Therapy</i> , 2018, 26, 1-2.	3.7	5
10	Toxicities associated with immunotherapies for hematologic malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 158-165.	0.7	14
11	Th3rapie cellulaire et cellules souches en 2018. <i>Revue Francophone Des Laboratoires</i> , 2018, 2018, 34-43.	0.0	0
12	Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3924.	1.8	41
13	Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. <i>Frontiers in Pharmacology</i> , 2018, 9, 1300.	1.6	602
14	Cytokine release syndrome: grading, modeling, and new therapy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 121.	6.9	99
15	Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials. <i>Experimental Cell Research</i> , 2018, 369, 1-10.	1.2	30
16	Comparing proteins and nucleic acids for next-generation biomolecular engineering. <i>Nature Reviews Chemistry</i> , 2018, 2, 113-130.	13.8	44
17	The Clinical Decision: A Clue to Health Services Outcomes Everywhere. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 515-519.	0.4	0
18	Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1007-1017.	0.9	45

#	ARTICLE	IF	CITATIONS
19	CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies. <i>Journal of Hematology and Oncology</i> , 2018, 11, 41.	6.9	44
20	CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 396-406.	1.2	113
21	Programming CAR-T cells to kill cancer. <i>Nature Biomedical Engineering</i> , 2018, 2, 377-391.	11.6	267
22	Driving the CAR to the Bone Marrow Transplant Program. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 561-569.	1.2	10
23	Utilization of CAR T Cell Therapy in Pediatric Patients. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150929.	0.7	3
25	Critical Care Management of Chimeric Antigen Receptor T Cell-related Toxicity. Be Aware and Prepared. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 20-23.	2.5	34
26	<p>Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2187-2191.	1.0	14
27	Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells. <i>Frontiers in Oncology</i> , 2019, 9, 241.	1.3	54
28	Mechanisms of resistance to CAR T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 372-385.	12.5	518
29	Targeting of IL-6-Relevant Long Noncoding RNA Profiles in Inflammatory and Tumorous Disease. <i>Inflammation</i> , 2019, 42, 1139-1146.	1.7	16
30	Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy. <i>Trends in Molecular Medicine</i> , 2019, 25, 412-427.	3.5	92
31	Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. <i>Journal of Hematology and Oncology</i> , 2019, 12, 17.	6.9	80
32	CAR T-cells: costs, comparisons, and commentary. <i>Journal of Medical Economics</i> , 2019, 22, 613-615.	1.0	42
33	One-step generation of modular CAR-T cells with AAV-Cpf1. <i>Nature Methods</i> , 2019, 16, 247-254.	9.0	101
34	Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3153-3163.	1.2	78
35	Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 1237.	1.3	106
36	The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 86-93.	2.0	21
37	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 625-638.	2.0	1,741

#	ARTICLE	IF	CITATIONS
38	Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nature Reviews Drug Discovery, 2019, 18, 197-218.	21.5	2,005
39	Prominent Precision Medicine Clinical Trials in Oncology Around the World. , 2019, , 571-592.		0
40	Nanomedicine and macroscale materials in immuno-oncology. Chemical Society Reviews, 2019, 48, 351-381.	18.7	118
41	The renal adverse effects of cancer immunotherapy. Journal of Nephrology, 2020, 33, 467-481.	0.9	6
42	Chimeric Antigen Receptor Therapies. , 2020, , 349-359.		0
43	Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy. Contemporary Clinical Trials, 2020, 96, 106083.	0.8	9
44	B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. International Journal of Molecular Sciences, 2020, 21, 5192.	1.8	24
45	Tumor-specific genetic profiling and therapy in biomedicine. , 2020, , 459-485.		0
46	Molecular and Cellular Modelling of Salivary Gland Tumors Open New Landscapes in Diagnosis and Treatment. Cancers, 2020, 12, 3107.	1.7	19
47	Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22910-22919.	3.3	32
48	Chemical Strategies to Boost Cancer Vaccines. Chemical Reviews, 2020, 120, 11420-11478.	23.0	95
49	Nongenetic Bioconjugation Strategies for Modifying Cell Membranes and Membrane Proteins: A Review. Bioconjugate Chemistry, 2020, 31, 2465-2475.	1.8	17
50	Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. Biomarker Research, 2020, 8, 18.	2.8	51
51	A three-dimensional hyaluronic acid-based niche enhances the therapeutic efficacy of human natural killer cell-based cancer immunotherapy. Biomaterials, 2020, 247, 119960.	5.7	37
52	Combination Therapies in Solid Tumour Oncology. , 2020, , 515-578.		0
53	CAR-T cells: the Chinese experience. Expert Opinion on Biological Therapy, 2020, 20, 1293-1308.	1.4	4
54	The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy, 2020, 22, 57-69.	0.3	70
55	Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Critical Reviews in Oncology/Hematology, 2021, 157, 103096.	2.0	10

#	ARTICLE	IF	CITATIONS
56	Medicina di precisione: miti e realtà. Medico E Bambino, 2021, 40, 18-24.	0.1	0
57	Gene Editing and Gene Therapies in Cancer Treatment. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 205-224.	0.1	0
58	The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth. Cellular Immunology, 2021, 360, 104262.	1.4	80
59	New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy. International Journal of Molecular Sciences, 2021, 22, 2404.	1.8	4
61	Customized immunology for precision medicine. JDDG - Journal of the German Society of Dermatology, 2021, 19, 335-336.	0.4	0
62	Nanotechnology synergized immunoengineering for cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 163, 72-101.	2.0	8
63	Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome. Leukemia and Lymphoma, 2021, 62, 2600-2611.	0.6	9
64	A Useful and Sustainable Role for Nâ€œfâ€œ Trials in the Healthcare Ecosystem. Clinical Pharmacology and Therapeutics, 2022, 112, 224-232.	2.3	25
65	Immunotherapy of Multiple Myeloma: Promise and Challenges. ImmunoTargets and Therapy, 2021, Volume 10, 343-371.	2.7	11
66	Chimeric antigen receptor T-cell therapy: An emergency medicine focused review. American Journal of Emergency Medicine, 2021, 50, 369-375.	0.7	2
67	Beyond the storm â€” subacute toxicities and late effects in children receiving CAR T cells. Nature Reviews Clinical Oncology, 2021, 18, 363-378.	12.5	37
68	Adoptive cell transfer (ACT) of autologous tumorâ€œinfiltrating lymphocytes (TILs) to treat malignant melanoma: the dawn of a chimeric antigen receptor T (CARâ€œT) cell therapy from autologous donor. International Journal of Dermatology, 2020, 59, 763-769.	0.5	8
69	A brief history of CAR-T cells: from laboratory to the bedside. Acta Haematologica Polonica, 2020, 51, 2-5.	0.1	32
70	Cytokine release syndrome after haploidentical hematopoietic stem cell transplantation with antithymocyte globulin: risk factors analysis and poor impact on outcomes for non-remission patients. Hematology, 2021, 26, 809-817.	0.7	3
71	The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy. International Reviews of Immunology, 2022, 41, 649-668.	1.5	7
72	Neue Arzneimittel 2018. , 2019, , 61-175.		1
73	CAR-dependent anti-metastatic activity of modified NK cell line YT. Genes and Cells, 2019, 14, 66-71.	0.2	1
76	Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments. Journal of Neuro-Oncology, 2022, 156, 81-96.	1.4	9

#	ARTICLE	IF	CITATIONS
78	Harnessing the Anti-Tumor Mediators in Mast Cells as a New Strategy for Adoptive Cell Transfer for Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 830199.	1.3	9
79	Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3067.	1.8	6
80	Neue Therapien in der Onkologie â€“ Wirkweise und Nebenwirkungen. <i>Onkologie Up2date</i> , 2021, 3, 289-307.	0.0	0
83	Human Tumor Targeted Cytotoxic Mast Cells for Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 871390.	1.3	14
84	Drawing Contingent Generalizations from Case Studies. , 2022, , 62-86.		2
85	Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments. <i>Cancers</i> , 2022, 14, 2408.	1.7	15
86	Contemplating Dichotomous Nature of Gamma Delta T Cells for Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	6
87	Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies. <i>Translational Oncology</i> , 2022, 22, 101459.	1.7	8
88	Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
89	Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy. <i>Current Cardiology Reviews</i> , 2022, 18, .	0.6	1
90	Enzyme Prodrug Therapy with Photo-Cross-Linkable Anti-EGFR Affibodies Conjugated to Upconverting Nanoparticles. <i>ACS Nano</i> , 2022, 16, 15873-15883.	7.3	2
91	Autologous Anti-CD19 CAR T-Cells immunotherapy in relapsed/refractory acute lymphoblastic leukemia patients. A systematic review and meta-analysis. , 2022, 101, .	0.0	0
92	Chimeric antigen receptor T (<sc>CARâ€“</sc>) cells: Novel cell therapy for hematological malignancies. <i>Cancer Medicine</i> , 2023, 12, 7844-7858.	1.3	15
93	CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. <i>Molecular Cancer</i> , 2023, 22, .	7.9	65
94	Deciphering the immune heterogeneity dominated by natural killer cells with prognostic and therapeutic implications in hepatocellular carcinoma. <i>Computers in Biology and Medicine</i> , 2023, 158, 106872.	3.9	2
95	â€œColdâ€•colorectal cancer faces a bottleneck in immunotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 240-250.	0.8	3
96	Transforming Diagnosis and Therapeutics Using Cancer Genomics. <i>Cancer Treatment and Research</i> , 2023, , 15-47.	0.2	1
107	Gene Editing and Gene Therapies in Cancer Treatment. , 2023, , 690-710.		0